Power3 Medical Products, Inc. Files for Patent on “Diagnosis of Early Stage Parkinson¡¯s Disease” (DrStockPick News Report!)

PWRM, Power 3 Medical Products Inc, PWRM.OB

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for Patent on

��Diagnosis of Early Stage Parkinson��s Disease��

 

Thursday August 6, 2009

Power3 Medical Products, Inc. Files for Patent on ��Diagnosis of Early Stage Parkinson��s Disease��

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced recently that the Company has filed a patent for ��Diagnosis of Early Stage Parkinson��s Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.��

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis of early stage Parkinson��s disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinson��s, in validation, utility, but that the importance of the Power3 protein biomarkers are statistically valid for use as a diagnostic test. This work was done in conjunction with Transgenomic, Inc. license/collaboration agreement. The patent provides coverage of biomarkers and the computation/statistical methods used to discriminate the disease vs. the normal controls.

��Power3 Medical is continuing the portfolio of it intellectual property in Neurodegenerative diagnosis��, We recently filed a patent on the ability of Power3;s Nuro-Pro-PD test, using a ser! ies of a bnormal blood serum biomarkers, to distinguish the early onset of Parkinson��s disease ,�� stated Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3. ��This patent is a break through declaration of new discoveries in this field��

��We are continually increasing our value with the exemplary patent filings for our biomarker discovery and validation. This is especially timely for the Nuro-Pro PD since we are striving to commercialize with our Collaborator, Transgenomic, Inc., via. CLIA testing in the late fall of 2009.�� Commented Ms. Helen R. Park, CEO of Power3. ��This adds value to Power3 and to our Licensee/Collaborator, Transgenomic, Inc.��

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Contact:

Power3 Medical Products, Inc., The Woodlands, TX
CEO
Helen R. Park, M.S., 281-466-1600
Fax: 281-466-1481
hpark@power3medical.com

www.power3medical.com
_________________________! ________ _______

Source: Power3 Medical Products, Inc.

Keep a close eye on PWRM today, do your homework, and like always BE READY for the ACTION!